Citation Impact
Citing Papers
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
Pathology of Nonalcoholic Fatty Liver Disease
2007
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
2004
Molecular mediators of hepatic steatosis and liver injury
2004 Standout
Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial
2010
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
2007
Thiazolidinediones
2004 Standout
Pathology of fatty liver disease
2007
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
2006 Standout
Recent concepts in non‐alcoholic fatty liver disease
2005
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD)
2008
mTOR Signaling in Growth Control and Disease
2012 Standout
Inflammation and metabolic disorders
2006 StandoutNature
Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome
2009
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
2009 StandoutNature
A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis
2008
Impact of obesity on treatment of chronic hepatitis C†
2006
Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
2010
A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease
2005
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
2008
Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease
2006
Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies
2004
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial
2004
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
2007 StandoutNobel
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
Antifibrotics for Chronic Hepatitis C
2009
A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients
2004
Hepatic MRI for Fat Quantitation
2005
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
2012 StandoutNature
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
2005 Standout
The metabolic syndrome
2010 Standout
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
2009
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
2005 Standout
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review
2006
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
2015 Standout
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
2004 Standout
A position statement on NAFLD/NASH based on the EASL 2009 special conference
2010
Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)
2010
Host Genetic Factors and Antiviral Immune Responses to Hepatitis C Virus
2008
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders
2007
Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy
2015
Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1
2006
Resolution of Nonalcoholic Steatohepatits after Gastric Bypass Surgery
2007
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
2007
Non-alcoholic fatty liver disease: The mist gradually clears
2008
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
2005 Standout
Role of Radiologic Modalities in the Management of Non-alcoholic Steatohepatitis
2007
One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study
2005
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents
2008
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
2008
Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease
2014
The metabolic syndrome
2005 Standout
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
2006
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
2007
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
2009
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
2006 Standout
Treating viral hepatitis C: efficacy, side effects, and complications
2006
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
2005 Standout
Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
2005
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
2009
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin
2007
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
2009
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
2011 Standout
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension Trial
2009
Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience
2011
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
2003 Standout
Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis
2008
Endocrine and liver interaction: the role of endocrine pathways in NASH
2009
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
2008
A long-range RNA–RNA interaction between the 5′ and 3′ ends of the HCV genome
2009
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
2005 Nature
Beyond insulin resistance in NASH: TNF-α or adiponectin?
2004
Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: Do androgens play a role?
2009
Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice
2010
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Hepatic histology in obese patients undergoing bariatric surgery
2006
Non-alcoholic fatty liver disease: current concepts and management strategies
2006
The functional RNA domain 5BSL3.2 within the NS5B coding sequence influences hepatitis C virus IRES-mediated translation
2011
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study
2006
Nonalcoholic steatohepatitis
2004
Mechanisms of fatty acid-induced inhibition of glucose uptake.
1994 Standout
Association of Nonalcoholic Fatty Liver Disease With Components of Metabolic Syndrome According to Body Mass Index in Korean Adults
2012
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study
2010
What We Talk About When We Talk About Fat
2014 Standout
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
2019
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
2004
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Nonalcoholic fatty liver disease and the metabolic syndrome
2005
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis
2010
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
2006
Hepatitis C virus 3′UTR regulates viral translation through direct interactions with the host translation machinery
2013 StandoutNobel
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2008
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
2009
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease
2011
Clinical trial: insulin‐sensitizing agents may reduce consequences of insulin resistance in individuals with non‐alcoholic steatohepatitis
2008
Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling
2006
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
2009
Hepatocellular Carcinoma
2011 Standout
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
2007
Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis
2006
Mechanisms of non-alcoholic steatohepatitis
2004
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites
2004
Nonalcoholic Fatty Liver Disease in Humans Is Associated with Increased Plasma Endotoxin and Plasminogen Activator Inhibitor 1 Concentrations and with Fructose Intake
2008
Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age
2010
Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies
2004
Liver-Directed Gamma Interferon Gene Delivery in Chronic Hepatitis C
2005 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
2005
Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens
2010
Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis
2004
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
2008
Fat and Beyond: The Diverse Biology of PPARγ
2008 Standout
Impaired insulin secretion and glucose intolerance in synaptotagmin-7 null mutant mice
2008 StandoutNobel
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
2009
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
2016
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
2007
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
Pathogenesis of Non-alcoholic Steatohepatitis: Human Data
2007
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
2009
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Human Fatty Liver Disease: Old Questions and New Insights
2011 StandoutScience
The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients #
2009
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
The prevalence of nonalcoholic fatty liver disease in the Americas
2014
Molecular mediators of hepatic steatosis and liver injury
2004 Standout
Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance
2003 StandoutScience
Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease
2009
Works of Alejandro Soza being referenced
Liver Transplantation Results for Hepatocellular Carcinoma in Chile
2010
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
2002
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
2004
Histological Resolution of Steatohepatitis After Iron Depletion
2004
Maintenance Therapy With Ribavirin in Patients With Chronic Hepatitis C Who Fail to Respond to Combination Therapy With Interferon Alfa and Ribavirin
2003
Analysis of natural variants of the hepatitis C virus internal ribosome entry site reveals that primary sequence plays a key role in cap-independent translation
2008
Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass
2005
Pilot study of interferon gamma for chronic hepatitis C
2005
Liver transplantation for hepatocellular carcinoma: evaluation of the alpha‐fetoprotein model in a multicenter cohort from Latin America
2016
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C
2003
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
2007
Non‐alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C‐reactive protein in Hispanics
2008
Increased Orocecal Transit Time in Patients with Nonalcoholic Fatty Liver Disease
2005
Pilot study of interferon gamma for chronic hepatitis C
2003
Evidence of intestinal bacterial overgrowth in patients with non-alcoholic steato-hepatitis
2001